Research ExplorerPublicationsDihydropyrimidine Dehydrogenase Testing prior to Treatment w...

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur

Standard

Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur : A Consensus Paper. / Wörmann, Bernhard; Bokemeyer, Carsten; Burmeister, Thomas; Köhne, Claus-Henning; Schwab, Matthias; Arnold, Dirk; Blohmer, Jens-Uwe; Borner, Markus; Brucker, Sara; Cascorbi, Ingolf; Decker, Thomas; de Wit, Maike; Dietz, Andreas; Einsele, Hermann; Eisterer, Wolfgang; Folprecht, Gunnar; Hilbe, Wolfgang; Hoffmann, Jürgen; Knauf, Wolfgang; Kunzmann, Volker; Largiadèr, Carlo R; Lorenzen, Sylvie; Lüftner, Diana; Moehler, Markus; Nöthen, Markus M; Pox, Christian; Reinacher-Schick, Anke; Scharl, Anton; Schlegelberger, Brigitte; Seufferlein, Thomas; Sinn, Marianne; Stroth, Matthias; Tamm, Ingo; Trümper, Lorenz; Wilhelm, Martin; Wöll, Ewald; Hofheinz, Ralf-Dieter.

In: ONCOL RES TREAT, Vol. 43, No. 11, 23.10.2020, p. 628-636.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Wörmann, B, Bokemeyer, C, Burmeister, T, Köhne, C-H, Schwab, M, Arnold, D, Blohmer, J-U, Borner, M, Brucker, S, Cascorbi, I, Decker, T, de Wit, M, Dietz, A, Einsele, H, Eisterer, W, Folprecht, G, Hilbe, W, Hoffmann, J, Knauf, W, Kunzmann, V, Largiadèr, CR, Lorenzen, S, Lüftner, D, Moehler, M, Nöthen, MM, Pox, C, Reinacher-Schick, A, Scharl, A, Schlegelberger, B, Seufferlein, T, Sinn, M, Stroth, M, Tamm, I, Trümper, L, Wilhelm, M, Wöll, E & Hofheinz, R-D 2020, 'Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper', ONCOL RES TREAT, vol. 43, no. 11, pp. 628-636. https://doi.org/10.1159/000510258

APA

Wörmann, B., Bokemeyer, C., Burmeister, T., Köhne, C-H., Schwab, M., Arnold, D., Blohmer, J-U., Borner, M., Brucker, S., Cascorbi, I., Decker, T., de Wit, M., Dietz, A., Einsele, H., Eisterer, W., Folprecht, G., Hilbe, W., Hoffmann, J., Knauf, W., ... Hofheinz, R-D. (2020). Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. ONCOL RES TREAT, 43(11), 628-636. https://doi.org/10.1159/000510258

Vancouver

Wörmann B, Bokemeyer C, Burmeister T, Köhne C-H, Schwab M, Arnold D et al. Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. ONCOL RES TREAT. 2020 Oct 23;43(11):628-636. https://doi.org/10.1159/000510258

Bibtex

@article{638e74a6bfc8483f9e7168c70f3ff135,
title = "Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper",
abstract = "BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%.SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.",
author = "Bernhard W{\"o}rmann and Carsten Bokemeyer and Thomas Burmeister and Claus-Henning K{\"o}hne and Matthias Schwab and Dirk Arnold and Jens-Uwe Blohmer and Markus Borner and Sara Brucker and Ingolf Cascorbi and Thomas Decker and {de Wit}, Maike and Andreas Dietz and Hermann Einsele and Wolfgang Eisterer and Gunnar Folprecht and Wolfgang Hilbe and J{\"u}rgen Hoffmann and Wolfgang Knauf and Volker Kunzmann and Largiad{\`e}r, {Carlo R} and Sylvie Lorenzen and Diana L{\"u}ftner and Markus Moehler and N{\"o}then, {Markus M} and Christian Pox and Anke Reinacher-Schick and Anton Scharl and Brigitte Schlegelberger and Thomas Seufferlein and Marianne Sinn and Matthias Stroth and Ingo Tamm and Lorenz Tr{\"u}mper and Martin Wilhelm and Ewald W{\"o}ll and Ralf-Dieter Hofheinz",
note = "{\textcopyright} 2020 S. Karger AG, Basel.",
year = "2020",
month = oct,
day = "23",
doi = "10.1159/000510258",
language = "English",
volume = "43",
pages = "628--636",
journal = "ONCOL RES TREAT",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "11",

}

RIS

TY - JOUR

T1 - Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur

T2 - A Consensus Paper

AU - Wörmann, Bernhard

AU - Bokemeyer, Carsten

AU - Burmeister, Thomas

AU - Köhne, Claus-Henning

AU - Schwab, Matthias

AU - Arnold, Dirk

AU - Blohmer, Jens-Uwe

AU - Borner, Markus

AU - Brucker, Sara

AU - Cascorbi, Ingolf

AU - Decker, Thomas

AU - de Wit, Maike

AU - Dietz, Andreas

AU - Einsele, Hermann

AU - Eisterer, Wolfgang

AU - Folprecht, Gunnar

AU - Hilbe, Wolfgang

AU - Hoffmann, Jürgen

AU - Knauf, Wolfgang

AU - Kunzmann, Volker

AU - Largiadèr, Carlo R

AU - Lorenzen, Sylvie

AU - Lüftner, Diana

AU - Moehler, Markus

AU - Nöthen, Markus M

AU - Pox, Christian

AU - Reinacher-Schick, Anke

AU - Scharl, Anton

AU - Schlegelberger, Brigitte

AU - Seufferlein, Thomas

AU - Sinn, Marianne

AU - Stroth, Matthias

AU - Tamm, Ingo

AU - Trümper, Lorenz

AU - Wilhelm, Martin

AU - Wöll, Ewald

AU - Hofheinz, Ralf-Dieter

N1 - © 2020 S. Karger AG, Basel.

PY - 2020/10/23

Y1 - 2020/10/23

N2 - BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%.SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.

AB - BACKGROUND: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side effects and the treatment-related mortality rate is 0.2-1.0%.SUMMARY: Among other risk factors associated with increased toxicity, a genetic deficiency in dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for the metabolism of FU, is well known. This is due to variants in the DPD gene (DPYD). Up to 9% of European patients carry a DPD gene variant that decreases enzyme activity, and DPD is completely lacking in approximately 0.5% of patients. Here we describe the clinical and genetic background and summarize recommendations for the genetic testing and tailoring of treatment with 5-FU derivatives. The statement was developed as a consensus statement organized by the German Society for Hematology and Medical Oncology in cooperation with 13 medical associations from Austria, Germany, and Switzerland. Key Messages: (i) Patients should be tested for the 4 most common genetic DPYD variants before treatment with drugs containing FU. (ii) Testing forms the basis for a differentiated, risk-adapted algorithm with recommendations for treatment with FU-containing drugs. (iii) Testing may optionally be supplemented by therapeutic drug monitoring.

U2 - 10.1159/000510258

DO - 10.1159/000510258

M3 - SCORING: Review article

C2 - 33099551

VL - 43

SP - 628

EP - 636

JO - ONCOL RES TREAT

JF - ONCOL RES TREAT

SN - 2296-5270

IS - 11

ER -